PLSE
Pulse Biosciences Inc

1,940
Mkt Cap
$975.85M
Volume
107,099.00
52W High
$25.00
52W Low
$12.56
PE Ratio
-12.68
PLSE Fundamentals
Price
$14.40
Prev Close
$14.86
Open
$14.80
50D MA
$15.03
Beta
1.35
Avg. Volume
177,411.79
EPS (Annual)
-$0.9176
P/B
10.52
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...
Business Wire·8d ago
News Placeholder
More News
News Placeholder
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.
Zacks·8d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5% - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Trading 5% Higher - Time to Buy...
MarketBeat·14d ago
News Placeholder
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
Zacks·17d ago
News Placeholder
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Technology
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or...
Business Wire·19d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Hits New 12-Month Low - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month Low - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Pulse Biosciences is Now Oversold (PLSE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Nasdaq News: Markets·2mo ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts...
MarketBeat·2mo ago
News Placeholder
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced plans...
Business Wire·2mo ago
News Placeholder
Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +6.45% and -82.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
<
1
2
...
>

Latest PLSE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.